Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb662 in Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb662 in Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XmAb 662 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Xencor

Most Recent Events

  • 06 Sep 2024 According to a Xencor media release, the company will host Research & Development Webcast and Conference call on monday, September 9, 2024, at 8:00 a.m. ET (5:00 a.m. PT), to provide updates on continued progress in dose escalation with first-in-class oncology programs.
  • 23 Aug 2024 Status changed from recruiting to discontinued.
  • 27 Feb 2024 According to a Xencor, media release, plans to conclude studies of XmAb564, complete internal data packages, and pause further development of both programs until after assessments of future data from competitor programs in this class and safety and biomarker data from Xencor studies in the first half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top